Caplin Point Laboratories Ltd, established in 1990, is a prominent Indian pharmaceutical company renowned for its innovative approach to addressing the healthcare needs of underserved markets. Initially focusing on manufacturing ointments and creams, the company has significantly diversified its product portfolio to include injectables, generics, and APIs (Active Pharmaceutical Ingredients). Caplin Point has strategically built a robust distribution network across emerging markets in Latin America, Africa, and Asia, owning its supply chain to ensure cost-effective and efficient delivery of high-quality medicines. This unique model allows the company to provide affordable healthcare solutions to regions traditionally lacking access to such services. Over the years, Caplin Point has achieved global recognition for adhering to stringent regulatory standards, earning approvals from renowned agencies like the US FDA and EU-GMP, enabling its expansion into regulated markets such as the USA and Europe. The company also emphasizes innovation through its dedicated Research & Development efforts, which focus on developing novel drug formulations and advanced delivery systems. Its subsidiary, Caplin Steriles, specializes in manufacturing sterile injectable products, further strengthening its market presence. By combining accessibility, affordability, sustainability, and a commitment to innovation, Caplin Point Laboratories Ltd continues to expand its global footprint, emerging as a distinguished leader in the pharmaceutical industry.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | |
| Promoters + | 70.62% | 70.62% | 70.56% | 70.56% | 70.56% |
| FIIs + | 2.84% | 3.33% | 3.38% | 3.71% | 4.86% |
| DIIs + | 0.43% | 1.08% | 1.49% | 1.83% | 2.11% |
| Public + | 26.11% | 24.95% | 24.59% | 23.93% | 22.48% |
| No. of Shareholders | 79,438 | 81,409 | 80,411 | 96,123 | 92,702 |
The shareholding pattern of Caplin Point Laboratories throughout 2024 reflects a dynamic and evolving ownership structure, showcasing growing interest from institutional investors. The Promoters held a consistent majority stake of 70.62% in December 2023 and March 2024, which slightly reduced to 70.56% in subsequent quarters, underscoring their continued strong control over the company. A notable development was the increasing stake of Foreign Institutional Investors (FIIs), which rose steadily from 2.84% in December 2023 to 4.86% by December 2024, signifying enhanced confidence among international investors in the company’s potential. Similarly, Domestic Institutional Investors (DIIs) expanded their holdings from a modest 0.43% in December 2023 to 2.11% by December 2024, reflecting growing domestic optimism in Caplin Point Laboratories and its strategic direction. Meanwhile, Public shareholding decreased from 26.11% in December 2023 to 22.48% by December 2024, indicating a gradual shift of ownership from retail investors to institutions. The number of shareholders also showed fluctuations, peaking at 96,123 in September 2024 before settling at 92,702 by the end of the year.
Below are the trading platforms that you can use to purchase Caplin Point Laboratories shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| April 2025 | 2,130.47 | 1,638.82 |
| May 2025 | 2,068.42 | 1,591.09 |
| June 2025 | 2,161.50 | 1,662.69 |
| July 2025 | 2,119.11 | 1,630.09 |
| August 2025 | 2,184.65 | 1,680.50 |
| September 2025 | 2,210.87 | 1,700.67 |
| October 2025 | 2,268.35 | 1,744.89 |
| November 2025 | 2,325.06 | 1,788.51 |
| December 2025 | 2,429.69 | 1,868.99 |
In 2025, the share prices of Caplin Point Laboratories are expected to exhibit a steady upward trend throughout the year. As we approach April 2025, the maximum price is anticipated to reach ₹2,130.47, while the minimum price is projected to be ₹1,638.82. Moving toward the latter months, as we step into December 2025, the share price is forecasted to achieve a maximum of ₹2,429.69 and a minimum of ₹1,868.99.
| When | Maximum Price | Minimum Price |
| January 2026 | 2,502.58 | 1,925.06 |
| February 2026 | 2,440.01 | 1,876.93 |
| March 2026 | 2,488.81 | 1,914.47 |
| April 2026 | 2,539.61 | 1,953.54 |
| May 2026 | 2,514.46 | 1,934.20 |
| June 2026 | 2,577.32 | 1,982.56 |
| July 2026 | 2,526.79 | 1,943.68 |
| August 2026 | 2,604.94 | 2,003.80 |
| September 2026 | 2,657.03 | 2,043.87 |
| October 2026 | 2,726.12 | 2,097.01 |
| November 2026 | 2,794.27 | 2,149.44 |
| December 2026 | 2,864.13 | 2,203.17 |
As we step into 2026, the share prices of Caplin Point Laboratories are projected to exhibit steady growth. In January 2026, the maximum price is expected to be ₹2,502.58, while the minimum price is likely to be ₹1,925.06. Throughout the year, the trend indicates a consistent upward momentum, and as we step into December 2026, the maximum price is forecasted to rise to ₹2,864.13, with the minimum price anticipated at ₹2,203.17.
| When | Maximum Price | Minimum Price |
| January 2027 | 2,892.77 | 2,225.21 |
| February 2027 | 2,966.94 | 2,282.26 |
| March 2027 | 3,082.65 | 2,371.27 |
| April 2027 | 3,022.21 | 2,324.78 |
| May 2027 | 2,934.18 | 2,257.06 |
| June 2027 | 3,066.22 | 2,358.63 |
| July 2027 | 3,006.10 | 2,312.38 |
| August 2027 | 3,099.07 | 2,383.90 |
| September 2027 | 3,207.54 | 2,467.34 |
| October 2027 | 3,290.93 | 2,531.49 |
| November 2027 | 3,373.21 | 2,594.78 |
| December 2027 | 3,457.54 | 2,659.64 |
| When | Maximum Price | Minimum Price |
| January 2028 | 3,526.69 | 2,712.84 |
| February 2028 | 3,617.12 | 2,782.40 |
| March 2028 | 3,758.18 | 2,890.91 |
| April 2028 | 3,684.49 | 2,834.23 |
| May 2028 | 3,577.18 | 2,751.68 |
| June 2028 | 3,738.15 | 2,875.50 |
| July 2028 | 3,664.85 | 2,819.12 |
| August 2028 | 3,778.20 | 2,906.31 |
| September 2028 | 3,910.44 | 3,008.03 |
| October 2028 | 4,012.11 | 3,086.24 |
| November 2028 | 4,112.41 | 3,163.39 |
| December 2028 | 4,215.22 | 3,242.48 |
| When | Maximum Price | Minimum Price |
| January 2029 | 4,299.53 | 3,307.33 |
| February 2029 | 4,409.77 | 3,392.13 |
| March 2029 | 4,581.75 | 3,524.42 |
| April 2029 | 4,491.91 | 3,455.32 |
| May 2029 | 4,361.08 | 3,354.68 |
| June 2029 | 4,557.33 | 3,505.64 |
| July 2029 | 4,467.97 | 3,436.90 |
| August 2029 | 4,606.16 | 3,543.20 |
| September 2029 | 4,767.37 | 3,667.21 |
| October 2029 | 4,891.32 | 3,762.56 |
| November 2029 | 5,013.61 | 3,856.62 |
| December 2029 | 5,138.95 | 3,953.03 |
| When | Maximum Price | Minimum Price |
| January 2030 | 5,241.72 | 4,032.10 |
| February 2030 | 5,376.13 | 4,135.48 |
| March 2030 | 5,585.80 | 4,296.77 |
| April 2030 | 5,476.27 | 4,212.52 |
| May 2030 | 5,316.77 | 4,089.82 |
| June 2030 | 5,556.02 | 4,273.86 |
| July 2030 | 5,447.08 | 4,190.06 |
| August 2030 | 5,615.55 | 4,319.65 |
| September 2030 | 5,812.09 | 4,470.84 |
| October 2030 | 5,963.21 | 4,587.08 |
| November 2030 | 6,112.29 | 4,701.76 |
| December 2030 | 6,265.09 | 4,819.30 |
As we move into 2030, the share prices of Caplin Point Laboratories are projected to demonstrate remarkable growth. In January 2030, the maximum price is expected to reach ₹5,241.72, with a minimum price of ₹4,032.10. This upward trajectory is likely to continue as the months progress, reflecting strong market confidence. By December 2030, the maximum price is anticipated to rise significantly to ₹6,265.09, while the minimum price is projected at ₹4,819.30, showcasing the sustained growth potential of Caplin Point Laboratories throughout the year.
Financial Condition of Caplin Point Laboratories
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,888 |
| Expenses + | 603 | 732 | 874 | 1,025 | 1,142 | 1,264 |
| Operating Profit | 260 | 329 | 395 | 442 | 552 | 624 |
| OPM % | 30% | 31% | 31% | 30% | 33% | 33% |
| Other Income + | 41 | 23 | 38 | 55 | 66 | 88 |
| Interest | 0 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 32 | 37 | 47 | 45 | 53 | 65 |
| Profit before tax | 269 | 314 | 386 | 451 | 564 | 646 |
| Tax % | 20% | 20% | 20% | 16% | 18% | |
| Net Profit + | 215 | 251 | 308 | 377 | 461 | 517 |
| EPS in Rs | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 67.81 |
| Dividend Payout % | 9% | 9% | 10% | 9% | 8% |
The financial performance of Caplin Point Laboratories over the period from March 2020 to the trailing twelve months (TTM) showcases its strong and consistent growth trajectory. The company’s sales have seen a significant increase, growing from ₹863 crore in March 2020 to ₹1,888 crore in TTM, reflecting its successful market expansion and ability to cater to rising demand. Correspondingly, expenses have grown from ₹603 crore to ₹1,264 crore during the same period, but the company has maintained operational efficiency. This is evident in the growth of its operating profit, which rose from ₹260 crore to ₹624 crore, with the Operating Profit Margin (OPM) improving from 30% to 33%. These figures demonstrate the company’s ability to effectively manage costs while capitalizing on revenue growth. Additionally, other income has seen a marked rise, from ₹41 crore in March 2020 to ₹88 crore in TTM, further contributing to its financial stability and profitability.
The company’s profitability metrics are equally impressive. Profit before tax increased substantially from ₹269 crore in March 2020 to ₹646 crore in TTM, underpinned by disciplined cost management and rising sales. Despite a fluctuating tax rate, net profit has shown remarkable growth, climbing from ₹215 crore to ₹517 crore during this period. Shareholder value has also improved significantly, with Earnings Per Share (EPS) rising from ₹28.42 in March 2020 to ₹67.81 in TTM. While Caplin Point Laboratories has maintained a moderate dividend payout ratio between 8% and 10%, this balanced approach highlights its focus on both rewarding shareholders and reinvesting in business growth.
FAQS
What is Caplin Point Laboratories market capitalization as of the latest available data?
Caplin Point Laboratories holds a market capitalization of ₹14,687 crore.
Caplin Point Laboratories is expected to reach ₹2,429.69 by the end of 2025.
Caplin Point Laboratories is projected to trade in a range between ₹4,032.10 to ₹6,265.09 in 2030.
Also Read:
- GMM Pfaudler Share Price Target 2025, 2026, 2027 to 2030
- Marsons Share Price Target 2025, 2026 to 2030
- KDDL Share Price Target 2025, 2026 to 2030
Should one invest in Caplin Point Laboratories?
Caplin Point Laboratories Ltd has demonstrated remarkable growth and resilience in its operations, financial performance, and market positioning. The company’s strategic focus on underserved markets, strong supply chain, and innovation-driven R&D efforts have solidified its status as a key player in the pharmaceutical industry. With consistent revenue growth, healthy operating profit margins, and increasing global regulatory approvals, Caplin Point is well-positioned for sustained success in both emerging and regulated markets. Its expanding institutional shareholding and steadily rising share prices further underscore strong investor confidence. As the company continues to leverage its innovative strategies and market expertise, it is poised for a promising future, contributing significantly to global healthcare solutions.
What did we learn?
- 1 Shareholdings Patterns of Caplin Point Laboratories
- 2 How to Purchases Caplin Point Laboratories Shares?
- 3 Caplin Point Laboratories Share Price Target: 2025 to 2030
- 3.1 Caplin Point Laboratories Share Price Target 2025
- 3.2 Caplin Point Laboratories Share Price Target 2026
- 3.3 Caplin Point Laboratories Share Price Prediction 2027
- 3.4 Caplin Point Laboratories Share Price Target 2028
- 3.5 Caplin Point Laboratories Share Price Prediction 2029
- 3.6 Caplin Point Laboratories Share Price Target 2030
- 4 Financial Condition of Caplin Point Laboratories
- 5 FAQS
- 6 Should one invest in Caplin Point Laboratories?
